Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of PHE885 BCMA-directed CAR-T in adults with relapsed and refractory multiple myeloma
MOH_2022-06-13_010700Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durcabtagene autoleucel in multiple myeloma (MM), sponsored by Novartis. Primary endpoint: Disease response by independent review committee. Started May 2022; status: completed.
02
Drugs
durcabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2022-06-13_010700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-13_010700.